276 drug centralized procurement of 11 provinces in Guangdong officially opened 58 exclusive varieties

The 276 drug collections in the 11-province alliance in Guangdong were officially opened, including 5 blood products and 58 exclusive varieties
.
The centralized procurement will be implemented in stages
.
This time, you can view the grouping and reporting volume of the first batch of companies that meet the application conditions, involving 579 companies and 1,613 product specifications
.
The viewing time is from now until 17:30 on February 25th
.
On February 23, the Guangdong Provincial Drug Trading Center issued the "Notice on Viewing the Information about Guangdong Alliance Diclofenac and Other Drugs Concentrated Procurement (First Batch) Registration Products".
The first batch of 579 companies and 1,613 products conformed to the application requirements.
condition
.
The "Notice" simultaneously discloses the reporting volume of the first batch of A/B purchase orders from public medical institutions in the alliance area (for details, see the attached table at the end of the article)
.
Among them, the pre-purchased volume in the first year of the purchase period of the representative specifications is 15.
082 billion (pieces/grain/bag/piece) in the same group, and the pre-purchased volume of the exclusive varieties in the first year of the purchase period of the representative specifications is 395 million (tablets/grain/piece).
bag/stick)
.
The number of varieties declared by the registered enterprises can also show the variety structure and scale of the enterprises
.
Among them, the top ones are: Ruiyang Pharmaceutical has 30 product specifications, Luoxin has 23, Baiyunshan Tianxin has 22, and Shuanglu has 21
.
The first batch of companies with 10 or more product specifications are shown in the table below: In addition, there are 2,602 product specifications and 208 companies in the second batch that meet the application requirements, and the time for information review and other work will be announced separately
.
The viewing time is from now until 17:30 on February 25th
.
The "Notice" clarifies that the lowest price is collected as of December 1, 2021 (inclusive) in all provinces (including Guangdong, Shanxi, Jiangxi, Henan, Guangxi, Hainan, Guizhou, Qinghai, Ningxia, Xinjiang, Xinjiang Production and Construction Corps) The lowest price (referring to the provincial online price or the provincial winning price)
.
The minimum price of the price declaration product specification and the minimum price of the benchmark product specification shall be the difference ratio
.
The lowest price with volume is the lowest selected price collected up to now in the national provincial-level procurement with volume
.
The "Notice" requires relevant enterprises to carefully check and check the price information of their related products.
If any undeclared or under-reported prices are found, please declare them truthfully within the specified time.
In addition to the above-mentioned materials, the declared price must be A letter of commitment for the lowest price of the above provinces (regions) as of December 1, 2021 (inclusive) (or the lowest selected price for provincial-level procurement with quantity in the country as of now)
.
If there is a circumstance listed in the "Procurement Documents" that "in the enterprises applying for the same product and the same competitive unit, the person in charge of the enterprise is the same person or there is a direct controlling or management relationship", the relevant enterprises are requested to make the declaration truthfully within the specified time.
The name of the specific competitive unit, the specific relationship with the competitive unit enterprise (the person in charge of the enterprise is the same person/there is a direct controlling relationship/there is a management relationship) and relevant certification materials.
For specific requirements and reporting methods, see the above "Feedback Methods and Requirements"
.
If the declaration is not made within the specified time, it shall be deemed that the enterprise undertakes that the above-mentioned situations do not exist
.
Review of relevant rules: On January 19, the Guangdong Provincial Drug Trading Center issued the "Guangdong Alliance Diclofenac and Other Drugs Centralized Procurement Documents", which clarified that 276 chemical drugs and therapeutic biological products with large consumption and high purchase amount in the national medical insurance catalogue are included in the list.
This collection
.
Among them, the drugs outside the national medical insurance list, the dosage forms or specifications of the national medical insurance list that has been collected and not expired, the drugs negotiated by the national medical insurance, the drugs under special management by the state, and the generic drugs that have passed (including deemed passed, the same below) consistency evaluation (As of November 4, 2021) The corresponding dosage form is not included in the scope of this collection
.
Purchasing cycle and purchasing agreement In principle, it shall not exceed two years, calculated from the actual implementation date of the selected/alternative results.
After the expiration of the first-year procurement period, it can be renewed for one year
.
The specific implementation time and procurement cycle are determined by the provinces in the alliance region themselves
.
The purchase agreement is signed once a year during the purchase cycle
.
When renewing the purchase agreement in the second year, re-quote the purchase volume.
In principle, the purchase volume of the second year agreement shall not be less than the first year agreement purchase volume of the selected/alternative product
.
In the first year of the procurement cycle, if the medical institution completes the agreed purchase volume of the year ahead of schedule, the part exceeding the agreed purchase volume will be given priority to purchase the selected/alternative products.
until the expiry of the purchasing cycle
.
During the implementation of the procurement cycle, if there is a duplication between the drugs purchased by the country and the drugs collected by the Guangdong Alliance this time, the results will be implemented according to the results of the national selection, and the purchase and sale contract will be re-signed
.
During the procurement cycle, after completing the agreed procurement volume, public medical institutions (including public medical institutions that have not reported the volume) will give priority to purchasing and using the selected products, and the selected/alternative products will continue to be purchased with a proportion of no less than 70% of the increment.
, the actual purchase volume of the alternative products that have not obtained incremental use shall not exceed the purchase volume reported by the corresponding public medical institution multiplied by the agreed procurement ratio in the first year
.
The purchase volume of medical insurance designated social medical institutions and designated pharmacies shall be implemented by both the supply and demand parties according to the agreement of the purchase agreement
.
Enterprise ladder quotation, minimum price requirements: 1.
The minimum price refers to the provinces (including Guangdong, Shanxi, Jiangxi, Henan, Guangxi, Hainan, Guizhou, Qinghai, Ningxia, Xinjiang and Xinjiang) as of December 1, 2021 (inclusive).
Production and Construction Corps) the lowest price (referring to the provincial-level online price or the provincial-level winning price)
.
Minimum daily cost = minimum price × average daily usage
.
Blood products, non-exclusive drugs and exclusive drugs shall be based on the product with the largest pre-purchased volume (referring to tablets/grains/bags/sticks, etc.
) of the same product in the first year reported by the public medical institutions in the alliance area.
The minimum price/minimum average daily cost of the standard product is lower than the minimum price/minimum average daily cost of the benchmark product
.
2.
The price of glucose/sodium chloride/glucose-sodium chloride injection is the same as the same product in the same group and in the same pack and different concentrations, and the lowest price is taken as the lowest price. .
The prices of small-volume injections with different contents below 10ml (inclusive) in the same enterprise and in the same group are not differentiated, and the lowest price with different contents below 10ml (inclusive) is taken as the lowest price
.
3.
Concentrated sodium chloride injection, physiological sodium chloride flushing agent and peritoneal dialysate injection, the same product of the same company, the same group, and the same packaging amount and different concentrations will not differentiate the price, and the lower value will be taken as the lowest price
.
The price of different fillings in the same group is calculated according to the difference of 0.
05 yuan for each increase (decrease) of 10ml per 10ml or more
.
The prices of small-volume injections with different contents below 10ml (inclusive) in the same enterprise and in the same group are not differentiated, and the lowest price with different contents below 10ml (inclusive) is taken as the lowest price
.
4.
Among blood products, non-exclusive drugs (except concentrated sodium chloride injection, physiological sodium chloride flushing agent and peritoneal dialysis liquid injection) and exclusive drugs, common powder injection, freeze-dried powder injection and solvent crystal in the same group of injections Powder injection does not distinguish between dosage forms and price differences; if a negative value appears in the mixed calculation of dosage form difference and content difference in injections, only the content difference price is calculated; for small-volume injections of the same type of the same company with the same content of less than 10ml (inclusive), take the same content.
The lowest price with the same content and different loadings shall be regarded as the lowest price
.
5.
For small-volume injections of biological products that use prefilled syringes to package single-dose medicines, the price of ordinary small-volume injections of the same product will be increased by 3 yuan for each; The price of ordinary small-volume injection is based on the price of the corresponding specification, and each injection is increased by 3 yuan (the pre-filled type is subject to the approval document issued by the State Drug Administration)
.
6.
There is no price difference between sugar-containing and non-sugar-containing products of the same variety, same dosage form and specification of the same company, and the lowest price of the same specification is taken as the lowest price
.